drugset / Trial / NCT04775602
Experimental Study to Evaluate the Impact of 18 Fluoro-PSMA (18F-PSMA) PET / CT in the Management of Patients with Prostate Cancer.
Phase 2
Completed
550 enrolled
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NaSingle-groupOpen-labelDiagnostic
Summary
Single-center, prospective, open-label, not randomized, diagnostic phase II trial in the management of patients with prostate cancer.
Timeline
- Start
- 2020-07-31
- Primary completion
- 2023-04-05
- Completion
- 2024-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-PSMA | Diagnostic / imaging agent | 200 mbq | Intravenous |
| Subject | 18F-PSMA | Diagnostic / imaging agent | 250 mbq | Intravenous |